Singapore markets closed

Atreca, Inc. (BCEL)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0800+0.0050 (+6.67%)
At close: 03:53PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.0750
Open0.0730
Bid0.2100 x 800
Ask0.2050 x 800
Day's range0.0730 - 0.0800
52-week range0.0520 - 1.2990
Volume81,225
Avg. volume8,563,675
Market cap3.17M
Beta (5Y monthly)1.17
PE ratio (TTM)N/A
EPS (TTM)-2.5000
Earnings date28 Mar 2024 - 01 Apr 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est5.50
  • GlobeNewswire

    Atreca Announces Asset Purchase Agreement for Sale of Antibody-Related Assets and Materials to Immunome

    CAMPBELL, Calif., Dec. 26, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (“Atreca”) (NASDAQ: BCEL), a biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today announced that it entered into a definitive asset purchase agreement with Immunome, Inc. (Nasdaq: IMNM) to sell a collection of antibody-related assets and materials. Under the terms of the agreement, Immunome would pay Atreca up t

  • GlobeNewswire

    Atreca Reports Third Quarter 2023 Financial Results and Announces Further Reorganization to Support Exploration of Strategic Alternatives

    SAN CARLOS, Calif., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Atreca, Inc. (Atreca) (NASDAQ: BCEL), a clinical-stage biotechnology company focused on developing novel therapeutics generated through a unique discovery platform based on interrogation of the active human immune response, today reported financial results for the third quarter ended September 30, 2023, and announced that the Company is implementing a further reduction in its workforce of approximately 40% while maintaining the necessary supp

  • Zacks

    Atreca (BCEL) Suspends Lead Drug Evaluation, Stock Falls 37%

    Atreca (BCEL) suspends the development of only pipeline candidate, ATRC-101, in clinical evaluation, as part of its business restructuring efforts and cuts headcount by 40%. The stock falls 37%.